KURA ONCOLOGY, INC. Debt Securities, Available-for-sale, Current
KURA ONCOLOGY, INC. (KURA) had Debt Securities, Available-for-sale, Current of $448.78 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Current $448.78M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $541.74M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $518.14M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $454.38M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $448.78M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $541.74M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $518.14M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $454.38M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $548.78M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $606.92M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $502.93M 10-K · filed 2026-03-05 |
| 2024-09-30 | $405.82M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $446.34M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $485.62M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $386.64M 10-K · filed 2025-02-28 |
| 2023-09-30 | $423.85M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $427.86M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $378.84M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $386.18M 10-K · filed 2024-02-27 |
| 2022-09-30 | $336.84M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $411.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $446.24M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $427.29M 10-K · filed 2023-02-23 |
| 2021-09-30 | $504.26M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $528.52M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $493.04M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $307.83M 10-K · filed 2022-02-24 |
| 2020-09-30 | $248.46M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $204.11M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $183.12M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $210.76M 10-K · filed 2021-02-24 |
| 2019-09-30 | $195.38M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $139.33M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $147.75M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $162.87M 10-K · filed 2020-02-25 |
| 2017-12-31 | $81.71M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |